Lab-Grown immune cells take aim at Life-Threatening viruses in vulnerable patients

NCT ID NCT06027879

ENROLLING_BY_INVITATION Disease control Sponsor: Paul Szabolcs Source: ClinicalTrials.gov ↗

First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time

Summary

This study tests whether specially grown immune cells can fight three common viruses—adenovirus, CMV, and EBV—in people whose immune systems are weak due to a stem cell or organ transplant, or an inherited immune disorder. The cells are made from a donor's blood and trained to recognize and attack the virus. The goal is to see if this treatment is safe and can clear the infection when standard therapies have failed.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
virus-specific T cells made using gamma capture technology
What this could lead to
If it works, this approach could offer a faster, more affordable way to treat dangerous viral infections in people with compromised immune systems, potentially saving lives.
What could go wrong
This is an early-phase trial with only 25 participants, so results may not apply to everyone. There is a risk of graft-versus-host disease or other immune reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADENOVIRUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • UPMC Children's Hospital of Pittsburgh

    Pittsburgh, Pennsylvania, 15224, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.